ReviewInternational journal of molecular sciences2015
Mass spectrometry-based proteomics for pre-eclampsia and preterm birth.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Trial
- Development of a predictive model for preeclampsia utilizing time-of-flight mass spectrometry based on novel nanomaterials integrated with machine learning.BMC pregnancy and childbirth · 2026Article
- Placental proteomic signatures of preterm birth, gestational age, and birthweight.BMC pregnancy and childbirth · 2025Article
- Exploratory Urinary Proteomic Profiling in Pregnancies with Fetal Aneuploidies: Molecular Insights into Maternal-Fetal Metabolic Communication.Current issues in molecular biology · 2025Article
- Evolution of the umbilical cord blood proteome across gestational development.Scientific reports · 2025Article
- The Coordinated Changes in Platelet Glycan Patterns with Blood Serotonin and Exosomes.International journal of molecular sciences · 2024Review
- Evolution of the Umbilical Cord Blood Proteome Across Gestational Development.medRxiv : the preprint server for health sciences · 2024Article
- The Role of Genetics in Preterm Birth.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- A proteomic profile of the healthy human placenta.Clinical proteomics · 2023Review
- Placental proteome in late‑onset of fetal growth restriction.Molecular medicine reports · 2022Article
- Human placental proteomics and exon variant studies link AAT/SERPINA1 with spontaneous preterm birth.BMC medicine · 2022Article
- Applications of Tandem Mass Spectrometry (MS/MS) in Protein Analysis for Biomedical Research.Molecules (Basel, Switzerland) · 2022Review
- Proteomic analysis of the umbilical cord in fetal growth restriction and preeclampsia.PloS one · 2022Article
- Screening and functional analysis of the differential peptides from the placenta of patients with healthy pregnancy and preeclampsia using placental peptidome.Frontiers in genetics · 2022Article
- Pre-eclampsia: pathogenesis, novel diagnostics and therapies.Nature reviews. Nephrology · 2019Review
- Article
- Prospective plasma proteome changes in preterm infants with different gestational ages.Pediatric research · 2018Article
- Translational Systems Pharmacology Studies in Pregnant Women.CPT: pharmacometrics & systems pharmacology · 2018Review
- Applications of Metabolomics in the Study and Management of Preeclampsia; A Review of the Literature.Metabolomics : Official journal of the Metabolomic Society · 2017Article
- Influence of random urine albumin-creatinine ratio of pregnant women with hypertension during the gestation period on perinatal outcome.Experimental and therapeutic medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy-related complications such as pre-eclampsia and preterm birth now represent a notable burden of adverse health. Pre-eclampsia is a hypertensive disorder unique to pregnancy. It is an important cause of maternal death worldwide and a leading cause of fetal growth restriction and iatrogenic prematurity. Fifteen million infants are born preterm each year globally, but more than one million of those do not survive their first month of life. Currently there are no predictive tests available for diagnosis of these pregnancy-related complications and the biological mechanisms of the diseases have not been fully elucidated. Mass spectrometry-based proteomics have all the necessary attributes to provide the needed breakthrough in understanding the pathophysiology of complex human diseases thorough the discovery of biomarkers. The mass spectrometry methodologies employed in the studies for pregnancy-related complications are evaluated in this article. Top-down proteomic and peptidomic profiling by laser mass spectrometry, liquid chromatography or capillary electrophoresis coupled to mass spectrometry, and bottom-up quantitative proteomics and targeted proteomics by liquid chromatography mass spectrometry have been applied to elucidate protein biomarkers and biological mechanism of pregnancy-related complications. The proteomes of serum, urine, amniotic fluid, cervical-vaginal fluid, placental tissue, and cytotrophoblastic cells have all been investigated. Numerous biomarkers or biomarker candidates that could distinguish complicated pregnancies from healthy controls have been proposed. Nevertheless, questions as to the clinically utility and the capacity to elucidate the pathogenesis of the pre-eclampsia and preterm birth remain to be answered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.